Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 341.50
-4.80 (-1.39%)
Sep 10, 2026, 5:24 PM IDT
Can-Fite BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.41 | 0.41 | 0.67 | 0.74 | 0.81 | 0.85 | |
Revenue Growth | -27.68% | -39.91% | -9.29% | -8.27% | -5.04% | 11.80% |
Gross Profit | 0.41 | 0.41 | 0.67 | 0.74 | 0.81 | 0.85 |
Selling, General & Admin | 3.02 | 3.66 | 3.05 | 2.96 | 3.14 | 3.85 |
Research & Development | 7.12 | 6.69 | 5.76 | 5.98 | 7.76 | 9.85 |
Operating Expenses | 10.14 | 10.36 | 8.8 | 8.94 | 10.91 | 13.7 |
Operating Income | -9.73 | -9.95 | -8.13 | -8.2 | -10.1 | -12.84 |
Interest & Investment Income | 0.34 | 0.28 | 0.29 | 0.51 | 0.22 | 0.02 |
Currency Exchange Gain (Loss) | -0.14 | -0.14 | -0.01 | 0.06 | -0.05 | 0.06 |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
EBT Excluding Unusual Items | -9.55 | -9.82 | -7.87 | -7.65 | -9.94 | -12.78 |
Gain (Loss) on Sale of Investments | -0 | -0 | -0.01 | 0.01 | -0.23 | 0.16 |
Pretax Income | -9.55 | -9.83 | -7.88 | -7.63 | -10.17 | -12.62 |
Earnings From Continuing Operations | -9.55 | -9.83 | -7.88 | -7.63 | -10.17 | -12.62 |
Net Income | -9.55 | -9.83 | -7.88 | -7.63 | -10.17 | -12.62 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 2.59 |
Net Income to Common | -9.55 | -9.83 | -7.88 | -7.63 | -10.17 | -15.21 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 3 | 2 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 3 | 2 | 1 | 0 | 0 | 0 |
Shares Change | 196.15% | 126.97% | 70.22% | 56.71% | 47.49% | 54.32% |
EPS (Basic) | -3.26 | -5.97 | -10.86 | -17.92 | -37.41 | -82.48 |
EPS (Diluted) | -3.26 | -5.97 | -10.86 | -17.92 | -37.41 | -82.48 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -9.51 | -8.95 | -7.64 | -8.44 | -10.81 | -9.87 |
Free Cash Flow Per Share | -3.24 | -5.44 | -10.54 | -19.81 | -39.76 | -53.53 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -2402.96% | -2456.79% | -1206.23% | -1102.96% | -1246.42% | -1505.51% |
Profit Margin | -2358.76% | -2426.67% | -1169.14% | -1027.46% | -1255.93% | -1782.53% |
Free Cash Flow Margin | -2348.89% | -2210.12% | -1133.83% | -1136.20% | -1334.57% | -1156.98% |
EBITDA | -9.73 | -9.93 | -8.12 | -8.18 | -10.08 | -12.83 |
D&A For EBITDA | 0 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 |
EBIT | -9.73 | -9.95 | -8.13 | -8.2 | -10.1 | -12.84 |